Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy

Pract Radiat Oncol. 2025 Jan-Feb;15(1):14-18. doi: 10.1016/j.prro.2024.10.014. Epub 2024 Nov 9.

Abstract

Treatment options for patients with metastatic castration-resistant prostate cancer include the use of radioligand therapy with 177Lu-PSMA-617. Although 177Lu-PSMA-617 can selectively target prostate cancer cells, salivary glands express PSMA on the apical lumen of the acinar epithelium. Xerostomia resulting from the use of radioligand therapy is common. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 2 dry mouth event after administration of 177Lu-PSMA-617. The patient was managed with oral hygiene and xerostomia mitigation strategies using oral rinses.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Dipeptides* / adverse effects
  • Dipeptides* / therapeutic use
  • Heterocyclic Compounds, 1-Ring* / adverse effects
  • Heterocyclic Compounds, 1-Ring* / therapeutic use
  • Humans
  • Lutetium* / adverse effects
  • Lutetium* / therapeutic use
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant* / pathology
  • Prostatic Neoplasms, Castration-Resistant* / radiotherapy
  • Radiopharmaceuticals / adverse effects
  • Radiopharmaceuticals / therapeutic use
  • Xerostomia* / etiology

Substances

  • Lutetium
  • Dipeptides
  • Heterocyclic Compounds, 1-Ring
  • Pluvicto
  • Radiopharmaceuticals
  • Prostate-Specific Antigen